EUCTR2011-003415-31-NO进行中（未招募）1 期
Randomized Phase II Study of Cabazitaxel versus Topotecan in Small Cell Lung Cancer Patients with Progressive Disease during or after a First Line Platinum Based Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 179
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •I 01. Histological/cytological proven locally advanced or metastatic small cell lung cancer with progressive disease during or after first line platinum based chemotherapy
- •I 02. Male or female =18 years (or country's legal age of majority if >18 years)
- •I 03. Patients with measurable disease, RECIST (version 1.1)
- •I 04. ECOG performance status =1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 103
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 69
排除标准
- •E 01. Absence of signed and dated Institutional Review Board (IRB)-approved patient informed consent form prior to enrollment into the study.
- •E 02. More than one prior chemotherapy regimen. Prior treatment with topotecan or taxanes.
- •E 03. Less than 28 days elapsed from prior treatment with chemotherapy, radiotherapy or surgery to the time of randomization. (Radiotherapy for bone pain palliation is allowed).
- •E 04. Adverse events (excluding alopecia) from any prior anticancer therapy of grade >1(National Cancer Institute Common Terminology Criteria [NCI CTCAE] v4.03) at the time of randomization.
- •E 05. Uncontrolled CNS metastases: patients with CNS metastases may have previous irradiation, only patients with SD or objective response to irradiation who are without CNS symptoms and on a maximum steroid dose of dexamethasone 8 mg daily or equivalent can be included.
- •E 06. Patients with known leptomeningeal metastases
- •E 07. History of other, invasive neoplasm requiring ongoing therapy.
- •E 08. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization
- •E 09. Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, NYHA class III or IV congestive heart failure, stroke or transient ischemic attack.
- •E 10. Any severe acute or chronic medical condition, which could impair the ability of the patient to participate in the study or interfere with interpretation of study results
- •E 11. Known HIV disease, or active hepatitis B or C (systematic testing is not required).
- •E 12. Pregnant or breast-feeding woman. Positive serum or urine pregnancy test prior to randomization
- •E 13. Patient with reproductive potential (M/F) who do not agree to use an accepted and effective method of contraception during the study treatment period and for at least 3 months after the completion of the study treatment. The definition of effective method of contraception will be based on the investigator's judgment. Effective method of contraception should also be adapted to local regulation.
- •E 14. History of hypersensitivity to polysorbate 80
- •E 15. Inadequate organ and bone marrow function as evidenced by:
- •o Hemoglobin <9.0 g/dL
- •o Absolute neutrophil count <1.5 x 10 exp9/L
- •o Platelet count <100 x 10exp9/L
- •o AST/SGOT and/or ALT/SGPT >2.5 x ULN
- •o AP >2.5 x ULN. In case of liver metastases AP > 5 x ULN
- •o Total bilirubin >1.0 x ULN
- •o Serum Creatinine >1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula, and creatinine clearance <60 mL/min will exclude the patient.
研究者
相似试验
进行中（未招募）
1 期
Cabazitaxel compared to topotecan for the treatment of small cell lung cancerSmall Cell Lung CancerEUCTR2011-003415-31-ESSanofi-aventis Recherche & Développement179
进行中（未招募）
不适用
Cabazitaxel compared to topotecan for the treatment of small cell lung cancerSmall Cell Lung CancerEUCTR2011-003415-31-PLSanofi-aventis Recherche & Développement172
进行中（未招募）
不适用
Pharmacokinetics and safety study of cabazitaxel in cancer patients with renal impairmentMedDRA version: 14.1Level: LLTClassification code 10041067Term: Small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Small Cell Lung CancerEUCTR2011-003415-31-ITSANOFI- AVENTIS RECHERCHE ET DÉVELOPPEMENT172
进行中（未招募）
不适用
Cabazitaxel compared to topotecan for the treatment of small cell lungcancerMedDRA version: 16.0Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 100000004864Small Cell Lung CancerEUCTR2011-003415-31-DESanofi-aventis Recherche & Développement172
进行中（未招募）
不适用
Cabazitaxel compared to topotecan for the treatment of small cell lung cancerMedDRA version: 14.1Level: PTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Small Cell Lung CancerEUCTR2011-003415-31-GRSanofi-aventis Recherche & Développement172